Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with hodgkin lymphoma: A report from the German Hodgkin Study Group

Blood

Volumn 123, Issue 11, 2014, Pages 1658-1664

  Eichenauer, Dennis A ^a   Thielen, Indra ^a   Haverkamp, Heinz ^a   Franklin, Jeremy ^a   Behringer, Karolin ^a   Halbsguth, Teresa ^a   Klimm, Beate ^a   Diehl, Volker ^a   Sasse, Stephanie ^a   Rothe, Achim ^a   Fuchs, Michael ^a   Bol̈l, Boris ^a   Von Tresckow, Bastian ^a   Borchmann, Peter ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INCIDENCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE; YOUNG ADULT;

EID: 84897530655     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-512657     Document Type: Article

References (33)

1. Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450-459.
2. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322(1):7-13. (Pubitemid 20023826)
3. Josting A, Wiedenmann S, Franklin J, et al German Hodgkin's Lymphoma Study Group. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(18):3440-3446. (Pubitemid 46594076)
4. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma. 2001;41(3-4):255-276. (Pubitemid 32499409)
5. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(10):1389-1398. (Pubitemid 350144157)
6. Litzow MR, Tarima S, Pérez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115(9):1850-1857.
7. Kayser S, Döhner K, Krauter J, et al German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137-2145.
8. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495-3502. (Pubitemid 47310889)
9. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
10. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica. 2010;95(Suppl. 2):A1146.
11. Engert A, Schiller P, Josting A, et al German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601-3608. (Pubitemid 46594052)
12. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.
13. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907-913.
14. Diehl V, Franklin J, Pfreundschuh M, et al German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [published correction appears in N Engl J Med. 2005;353(7):744]. N Engl J Med. 2003;348(24):2386-2395. (Pubitemid 36682817)
15. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234-4242.
16. Engert A, Haverkamp H, Kobe C, et al German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799.
17. Behringer K, Wildt L, Mueller H, et al German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052-2060.
18. Sieber M, Bredenfeld H, Josting A, et al German Hodgkin's Lymphoma Study Group. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(9):1734-1739. (Pubitemid 46638585)
19. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12(8):737-751. (Pubitemid 23134304)
20. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
21. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
22. Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst. 2006;98(3):215-218. (Pubitemid 43205483)
23. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986;4(6):830-837. (Pubitemid 16080935)
24. Brusamolino E, Anselmo AP, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica. 1998;83(9):812-823. (Pubitemid 28496170)
25. Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013;31(5):592-598.
26. Delwail V, Jais JP, Colonna P, Andrieu JM. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002;118(1):189-194. (Pubitemid 34779536)
27. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
28. Federico M, Luminari S, Iannitto E, et al; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805-811.
29. Viviani S, Zinzani PL, Rambaldi A, et al Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-212.
30. Carde PP, Karrasch M, Fortpied C, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles = > 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. ASCO Meeting Abstracts. 2012;30:8002.
31. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943-952.
32. Spina F, Alessandrino PE, Milani R, et al. Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. Leuk Lymphoma. 2012;53(1):96-102.
33. Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts. 2012;120:547.